1. The novel Xeno-free CTS Immune Cell Serum Replacement (SR) is a defined component serum replacement that can be used to produce clinical grade T-cell therapies in combination with several different cell culture media.
2. The SR supported the optimal expansion of T cells specific for subdominant tumour-associated antigens and promoted expansion of T cells with central memory T-cell phenotype, which is favourable for in vivo survival and persistence following adoptive transfer.
3. The SR also supported highly amenable lentivirus-mediated gene transduction for potential application for gene-modified T cells.
The article provides a detailed description of the novel Xeno-free CTS Immune Cell Serum Replacement (SR) and its potential applications in the production of clinical grade adoptive cellular therapies. The authors provide evidence from multiple experiments to demonstrate that the SR supports the optimal expansion of T cells specific for subdominant tumour-associated antigens, promotes expansion of T cells with central memory T-cell phenotype, and supports highly amenable lentivirus-mediated gene transduction for potential application for gene-modified T cells.
The article appears to be reliable and trustworthy as it provides evidence from multiple experiments to support its claims. Furthermore, the authors have provided detailed descriptions of their methods and results, which allows readers to assess the validity of their findings. However, there are some points that could be further explored in future studies such as exploring other potential applications of the SR or comparing its efficacy with other existing serum replacements on the market. Additionally, it would be beneficial if more information was provided on possible risks associated with using this serum replacement as well as any potential side effects or adverse reactions that may occur when using it in clinical settings.